The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Ferritin acts as a robust biomarker for patient prognosis
Erman Akkus, MD, Ankara University Medical School, Ankara, Turkey, highlights the link between serum ferritin levels and survival outcomes in advanced biliary tract cancer. Despite treatment advances, reliable biomarkers are still lacking to determine patient suitability for treatment regimes. His findings support serum ferritin as a strong prognostic biomarker, as elevated levels correlate with shorter progression-free and overall survival. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In the recent years, there have been a lot of progress in the treatment of bladder tract cancers, indeed. Especially in the first line, adding immunotherapy to the splinted gemcitabine. And for the second-line treatment, a lot of targeted treatments were studied and reported to be effective. But still, we use chemotherapy a lot in daily practice, in most of the countries, the targeted treatments are not available...
In the recent years, there have been a lot of progress in the treatment of bladder tract cancers, indeed. Especially in the first line, adding immunotherapy to the splinted gemcitabine. And for the second-line treatment, a lot of targeted treatments were studied and reported to be effective. But still, we use chemotherapy a lot in daily practice, in most of the countries, the targeted treatments are not available. So, despite these advancements in the treatment of bladder tract cancer, still we don’t know which patients benefit more or not. So, we need biomarkers and patient selection in patients treated with first-line treatment in bladder tract cancer. So in our study, we analyzed retrospectively the bladder tract cancer patients treated with first-line treatment. And we see that the high serum ferritin level is prognostic for progression-free survival and overall survival. Although our cohort included only patients treated with chemotherapy, it should be investigated in patients who received chemoimmunotherapy also. But the hazard ratio is so remarkable that for progression-free survival it’s around 5 and for overall survival it’s around 12. So it means that the high ferritin level may be a robust biomarker for bladder tract cancers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
